CCO Treatment Updates

The Clinical Impact of Next-Generation NNRTIs: Recent Research and Practical Treatment Strategies

Questions And Answers

Review the answers to Clinical Care Options member questions on next-generation NNRTIs posted by our expert faculty. If you do not find what you are looking for, you can submit your own question.

What Should a Clinician Remember When Deciding Which of the Recently Approved Agents to Use in a Treatment-Experienced Patient?
Can We Be Confident That Initial Activity of Etravirine Will Be Durable?
Is a Virtual Phenotype More or Less Useful Than Counting the Number of Etravirine Resistance Associated Mutations?
Should I Be Concerned With Minority Variants When Prescribing Antiretroviral Regimens in Treatment-Naive Patients? In Treatment-Experienced Patients?
Should a Patient Be Switched to an Etravirine-Based Regimen After Failing a First-Line NNRTI-Based Regimen to Defer the Use of Other Antiretroviral Classes?
Will the Choice of Initial NNRTI Affect the Efficacy of Etravirine in Subsequent Regimens?
What Is the Recommended Dosing and Total Pill Count for the Next-Generation NNRTIs?
What Are the Half-Lives of the Next-Generation NNRTIs?
Are Any of the Next-Generation NNRTIs Associated With CNS Adverse Effects?
How Many Mutations Are Required for HIV to Develop Resistance to Next-Generation NNRTIs?
Can Etravirine be Used in Patients Receiving TB Treatment?
Should Etravirine Be Used to Treat Antiretroviral-Naive Patients With Transmitted NNRTI Resistance?
What Are the Main Adverse Effects Associated With Etravirine?
Should Etravirine Be Given to Pregnant Women?
What Data Are Available for UK-453,061?
Should I Use Darunavir/Ritonavir With Etravirine or Tipranavir/Ritonavir Without Etravirine in my Treatment-Experienced Patient?
Should Etravirine Always Be Combined With a Boosted PI?
When Will Future NNRTIs Be Available?
Can Susceptibility to Etravirine Be Assessed From Past Resistance Tests?
Is There a Clinical Need for Next-Generation NNRTIs in Initial Therapy?

Faculty Answers Questions on Next-Generation NNRTIs (coming soon)

Module 1 of 2

Faculty:
Eric S. Daar, MD Joseph J. Eron, Jr., MD Anton L. Pozniak, MD, FRCP

CME CREDIT INFORMATION

Release Date: --

Expiration Date: --

Physicians: maximum of 1.25 AMA PRA Category 1 Credit(s)™

Status: Please log in to view status

Eric S. Daar, MD; Joseph J. Eron, Jr., MD; and Anton L. Pozniak, MD, FRCP, answer questions on the next generation of NNRTIs.

Learning Objectives

Upon completion of this activity, participants should be able to:

Cite the adverse events associated with the use of etravirine
Discuss which patient populations have the most potential to benefit from etravirine-based antiretroviral therapy
Explain the potential clinical applications of next-generation NNRTIs
Describe next-generation NNRTIs in early clinical and preclinical development

The Next Generation of NNRTIs

Module 2 of 2

Faculty:
Anton L. Pozniak, MD, FRCP

CME CREDIT INFORMATION

Release Date: 09/14/07

Expiration Date: 09/13/08

Physicians: maximum of 1.25 AMA PRA Category 1 Credit(s)™

Status: Please log in to view status

Anton L. Pozniak, MD, FRCP, discusses the need for novel next-generation of NNRTIs, the future of this drug class, and current NNRTIs in clinical development.

Learning Objectives

Upon completion of this activity, participants should be able to:

Identify the strengths and limitations of the first-generation NNRTIs
Discuss data from randomized clinical trials investigating next-generation NNRTIs
Describe next-generation NNRTIs in early clinical and preclinical development

Virtual Presentations

The Clinical Need for Next-Generation NNRTIs

Faculty:
Eric S. Daar, MD

CME CREDIT INFORMATION

Release Date: 07/13/07

Expiration Date: 07/12/08

Physicians: maximum of 0.75 AMA PRA Category 1 Credit(s)™

Status: Please log in to view status

Eric S. Daar, MD, reviews data from clinical trials that highlight the strengths and weaknesses of the currently available NNRTIs and discusses the clinical need for a next generation of NNRTIs.

Learning Objectives

Upon completion of this activity, participants should be able to:

Recall data from clinical trials highlighting the strengths and weaknesses of the currently approved NNRTIs
Describe how transmitted NNRTI resistance mutations could influence treatment outcomes
Discuss the potential clinical benefit of next-generation NNRTIs

The Clinical Need for Next-Generation NNRTIs

Format: Microsoft PowerPoint (.ppt) | File size: 936 KB

The Potential Clinical Impact of Next-Generation NNRTIs

Faculty:
Joseph J. Eron, Jr., MD

CME CREDIT INFORMATION

Release Date: 09/05/07

Expiration Date: 09/04/08

Physicians: maximum of 0.75 AMA PRA Category 1 Credit(s)™

Status: Please log in to view status

Joseph J. Eron, Jr., MD, discusses the potential impact of next-generation NNRTIs on the management of HIV-infected patients based on the results of clinical trials.

Learning Objectives

Upon completion of this activity, participants should be able to:

Recall the clinical strengths and weaknesses of the first-generation NNRTIs
Describe data from clinical trials investigating next-generation NNRTIs
Discuss the potential clinical applications of the next-generation NNRTIs

The Potential Clinical Impact of Next-Generation NNRTIs

Format: Microsoft PowerPoint (.ppt) | File size: 1,053 KB

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.